IL164011A0 - Antagonistic anti-hfas ligand human antibodies andfragments thereof - Google Patents
Antagonistic anti-hfas ligand human antibodies andfragments thereofInfo
- Publication number
- IL164011A0 IL164011A0 IL16401103A IL16401103A IL164011A0 IL 164011 A0 IL164011 A0 IL 164011A0 IL 16401103 A IL16401103 A IL 16401103A IL 16401103 A IL16401103 A IL 16401103A IL 164011 A0 IL164011 A0 IL 164011A0
- Authority
- IL
- Israel
- Prior art keywords
- human antibodies
- hfasl
- antibodies
- andfragments
- fas ligand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36705402P | 2002-03-21 | 2002-03-21 | |
US40976802P | 2002-09-10 | 2002-09-10 | |
PCT/US2003/006155 WO2003079750A2 (en) | 2002-03-21 | 2003-03-12 | ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
IL164011A0 true IL164011A0 (en) | 2005-12-18 |
Family
ID=28457146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16401103A IL164011A0 (en) | 2002-03-21 | 2003-03-12 | Antagonistic anti-hfas ligand human antibodies andfragments thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US7262277B2 (xx) |
EP (1) | EP1490405B1 (xx) |
JP (1) | JP2005520523A (xx) |
CN (1) | CN1283662C (xx) |
AT (1) | ATE370970T1 (xx) |
AU (1) | AU2003219954B2 (xx) |
BR (1) | BR0308401A (xx) |
CA (1) | CA2478386A1 (xx) |
DE (1) | DE60315815T2 (xx) |
DK (1) | DK1490405T3 (xx) |
ES (1) | ES2291626T3 (xx) |
IL (1) | IL164011A0 (xx) |
MX (1) | MXPA04009148A (xx) |
PT (1) | PT1490405E (xx) |
WO (1) | WO2003079750A2 (xx) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
EA202091901A1 (ru) | 2003-11-05 | 2020-11-24 | Роше Гликарт Аг | АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ |
LT2857418T (lt) | 2004-02-06 | 2017-09-25 | University Of Massachusetts | Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas |
CN101291954B (zh) * | 2005-08-26 | 2013-03-27 | 罗氏格黎卡特股份公司 | 具有改变的细胞信号传导活性的修饰的抗原结合分子 |
US20110038867A1 (en) * | 2007-12-12 | 2011-02-17 | Carlo Pincelli | Remedies for pemphigus containing anti fas ligand antibodies |
EP2318441A2 (en) * | 2008-07-14 | 2011-05-11 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
CA2746334C (en) * | 2008-12-12 | 2018-06-12 | Pincell Srl | Remedies for pemphigus containing anti fas ligand antibodies |
CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
JP2016508606A (ja) * | 2013-02-01 | 2016-03-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | トリプルネガティブ乳ガンにおける転移を予測及び予防するための方法 |
BR112015027249A2 (pt) * | 2013-04-29 | 2017-09-26 | Apogenix Gmbh | método de diagnóstico de câncer |
EP3137909B1 (en) * | 2014-04-29 | 2018-06-06 | Apogenix AG | Diagnostic anti-cd95l antibody |
US20220289827A1 (en) * | 2021-03-11 | 2022-09-15 | Washington University | Neutralizing antibodies to sars-cov-2 and its variants |
CN116888257A (zh) * | 2022-01-21 | 2023-10-13 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
CN116829594A (zh) * | 2022-01-21 | 2023-09-29 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08127594A (ja) * | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Fas抗原に結合する新規蛋白質およびそれをコードするDNA |
JPH09508009A (ja) | 1994-01-07 | 1997-08-19 | イミュネックス・コーポレーション | Fas抗原を結合するリガンド |
US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
NZ311174A (en) * | 1995-06-30 | 1999-04-29 | Mochida Pharm Co Ltd | Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody |
US6096312A (en) * | 1995-06-30 | 2000-08-01 | Mochida Pharmaceutical Co., Ltd. | Agent for suppressing a reduction of CD4+ lymphocytes |
-
2003
- 2003-03-12 IL IL16401103A patent/IL164011A0/xx unknown
- 2003-03-12 AU AU2003219954A patent/AU2003219954B2/en not_active Ceased
- 2003-03-12 WO PCT/US2003/006155 patent/WO2003079750A2/en active IP Right Grant
- 2003-03-12 DK DK03716239T patent/DK1490405T3/da active
- 2003-03-12 ES ES03716239T patent/ES2291626T3/es not_active Expired - Lifetime
- 2003-03-12 CA CA002478386A patent/CA2478386A1/en not_active Abandoned
- 2003-03-12 CN CNB038064030A patent/CN1283662C/zh not_active Expired - Fee Related
- 2003-03-12 JP JP2003577595A patent/JP2005520523A/ja active Pending
- 2003-03-12 AT AT03716239T patent/ATE370970T1/de not_active IP Right Cessation
- 2003-03-12 US US10/506,743 patent/US7262277B2/en not_active Expired - Fee Related
- 2003-03-12 EP EP03716239A patent/EP1490405B1/en not_active Expired - Lifetime
- 2003-03-12 PT PT03716239T patent/PT1490405E/pt unknown
- 2003-03-12 MX MXPA04009148A patent/MXPA04009148A/es active IP Right Grant
- 2003-03-12 BR BR0308401-9A patent/BR0308401A/pt not_active IP Right Cessation
- 2003-03-12 DE DE60315815T patent/DE60315815T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
BR0308401A (pt) | 2005-03-29 |
ES2291626T3 (es) | 2008-03-01 |
DE60315815T2 (de) | 2008-05-21 |
DK1490405T3 (da) | 2007-12-27 |
US20050106140A1 (en) | 2005-05-19 |
MXPA04009148A (es) | 2005-02-28 |
PT1490405E (pt) | 2007-11-07 |
AU2003219954A1 (en) | 2003-10-08 |
EP1490405B1 (en) | 2007-08-22 |
JP2005520523A (ja) | 2005-07-14 |
CN1642980A (zh) | 2005-07-20 |
US7262277B2 (en) | 2007-08-28 |
ATE370970T1 (de) | 2007-09-15 |
WO2003079750A2 (en) | 2003-10-02 |
EP1490405A2 (en) | 2004-12-29 |
CA2478386A1 (en) | 2003-10-02 |
DE60315815D1 (de) | 2007-10-04 |
AU2003219954B2 (en) | 2006-11-09 |
EP1490405A4 (en) | 2005-09-14 |
WO2003079750A3 (en) | 2004-05-13 |
CN1283662C (zh) | 2006-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006740A (es) | Anticuerpos humanos que se unen a la il-12 humana y metodos para producirlos. | |
TW200738749A (en) | Human antibodies that bind human IL-12 and methods for producing | |
NO2017038I1 (no) | Adalimumab - Forlenget SPC | |
BG111004A (bg) | Антитела, които се свързват с човешки интерлевкин-18, и методи за получаване и използване | |
MXPA04001344A (es) | Anticuerpos humanos antagonistas contra htnfsf13b. | |
EP2395020A3 (en) | IL-18 binding proteins | |
TW200745160A (en) | IL-12/P40 binding proteins | |
IL164011A0 (en) | Antagonistic anti-hfas ligand human antibodies andfragments thereof | |
WO2005016951A3 (en) | Anti-ghrelin fab antibodies | |
SG163559A1 (en) | Il-12/p40 binding proteins | |
MY150711A (en) | Il-12/p40 binding proteins | |
MX343996B (es) | Anticuerpos humanos que ligan el tnfa humano. |